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A B S T R A C T
Lyme disease has not been officially reported in Cuba. However, clinical cases have been 
serologically reported. Seroprevalence survey of Borrelia burgdorferi sensu stricto antibodies in 
humans in the country has not been conducted. 
Objective: To estimate the prevalence of borrelial antibodies in inhabitants of a village with 
historically high level of tick infestation. 
Methods: Serum specimens from 247 persons randomly selected from the population of the 
village were examined by IgG Western blot using B31 strain for estimating the prevalence of 
antibodies profile. 
Results: A seroprevalence value interval (95% CI) of 0.6%-7.2% was estimated for the studied 
population. The prevalent borrelial protein bands on immunoblots were 41, 72, 90/93, 34, 47, 60, 
58, 56, 65/66 and 31 kDa in a decreasing order of significance.
Conclusion: These results support the previous serological findings, suggesting the presence of 
this borreliosis in Cuba.
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Lyme disease, a multisystem inflammatory disorder caused by 
the spirochaetal complex Borrelia burgdorferi sensu lato, is the 
most frequently reported vector-borne infectious disease in 
the Northern hemisphere. The human infection is transmitted 
by ixodid tick bites and caused primarily by three pathogenic 
genospecies, B. burgdorferi sensu stricto, Borrelia garinii and 
Borrelia afzelii.1 In North America, B. burgdorferi sensu stricto is 
the sole cause of the infection; in Europe, the three genospecies 
can cause the disease, while B. garinii and B. afzelii can be found 
in Asia. In addition, other 15 closely related Borrelia species have 
been identified, but only Borrelia lusitaniae, Borrelia valaisiana and 
Borrelia spielmani cause human infections.1-3
The disorder develops in stages and has different 
manifestations that mainly involve the skin, nervous systems, 
heart and joints; although some infected people have no 
symptoms, up to 20% may not show the characteristic skin 
manifestations, and many patients also have no (or mild) 
systemic symptoms at presentation.4
The diagnosis of Lyme borreliosis is based on the recognition 
of typical clinical signs and is assisted by laboratory tests, of 
which antibody detection methods are preferred.5
This illness represents a considerable emerging infectious 
disease threat because of its consequences to human 
health and the difficulties in preventing and controlling it. 
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The morbidity rates continually increase in some geographical 
areas. This may be due to the actual spread of the disease and/
or alternatively to improved diagnostic methods.4
In Cuba, Lyme disease has not been officially reported, 
although specific antibodies against B. burgdorferi sensu lato 
complex, measured by ELISA and Western blot techniques, 
have been found in individuals that have presented compatible 
clinical manifestations with this borreliosis.6-8
The aim of the present study was to estimate the prevalence 
of specific antibodies to B. burgdorferi sensu stricto in a human 
population from Cuba, in order to continue the investigations 
about the presence of this pathogen in the country. 
The studied population lives in one of the villages located 
in Sierra del Rosario, in the Eastern part of the mountainous 
area of Guaniguanico, between Pinar del Rio and Artemisa 
provinces, Cuba. It is a small rural area with the following 
climatological conditions: 24.4°C as multiannual average 
temperature and 2013.9 mm as annual average rainfall.9 
Such conditions are favorable for the survival of different tick 
species. This place was selected because it has had high level 
of tick infestation historically, mainly Amblyomma cajennsense 
(a three-host ixodid tick) and because it was there that the first 
Cuban cases of Lyme disease were serologically reported.6,7
From the total number of inhabitants (n = 980) in this village, 
247 were invited to take part in the study from January to May 
2006, selected by a random simple sampling. All of them were 
adults. The serosurvey was conducted with the consent of 
subjects in compliance with the Declaration of Helsinki. One 
serum specimen per subject was collected and transported to 
the ADMed Microbiology Laboratory of La-Chaux-de-Fonds, 
Switzerland, according to the International Air Transport 
Association recommendations. 
An in-house Western blot, a validated and standardized system 
used as confirmatory test in the routine diagnosis, was used for the 
detection of IgG in the sera. Briefly, a bacterial protein suspension 
was prepared from B. burgdorferi sensu stricto (B31) and a protein 
profile was made by its electrophoretic separation and transferred 
to nitrocellulose membranes with semi-dry apparatus (Biorad, 
France), according to standard laboratory procedures. Human 
sera diluted 1:200 were added to the membranes, followed by the 
addition of alkaline phosphatase labeled goat anti-human IgG 
(diluted 1:500) (Kirkegaard & Perry Laboratories, USA). A negative 
and a positive sample were added for each assay.
The borrelial antibodies profile obtained in the blots for 
the studied population sample and in the individual blots 
estimated as positives were analyzed and described.
The North American strain B31 was used as antigen because 
Cuba is very close, from a geographically viewpoint, to the United 
States of America, it is in the way of migratory birds and any other 
genospecies has not been reported in the American continent. It 
is known that reliability of serological investigations increases 
when antibodies are measured against the antigens of Borrelia 
spp. occurring in a particular geographic area.10
Band intensities were determined by visual comparison 
with band intensities for the positive control, and they were 
graded in: 0 (when traces were observed), and from 1+ to 4+ 
according to the intensities. Zero was not counted and given 
as negative, 1+ was interpreted as weak result and 2+ to 4+ 
were interpreted as strong results. Data were stored in an Excel 
sheet (Microsoft Office) for analysis. 
According to the ADMed Microbiology laboratory criteria 
(based on the total addition of the scores assigned to each band, 
in accordance to the bands’ specificities) the seroprevalence rate 
was 2.02% (5/247) (95% CI, 0.6%-4.7%). The same result was found 
when we used the Centers for Disease Control and Prevention 
(CDC) criteria for a Western blot-IgG, criteria recommended in 
the American region.11 However, when we used the CDC criteria 
with the inclusion of OspA and OspB proteins suggested by 
Hilton et al.,12 the seroprevalence rate was 4.45% (11/247) (95% 
CI, 1.7%-7.2%). Then, we could estimate a prevalence of specific 
borrelial antibodies in the studied population of 0.6%-7.2% as 
result of the union of confidence intervals.
The sera identified as positives were tested by Rapid Plasma 
Reagin test (Centis Diagnosticos, Cuba), Treponema pallidum 
haemagglutination assay (Centis Diagnosticos, Cuba) and 
microagglutination test in order to search for cross-reactions with 
treponemal and leptospiral antibodies, because cross-reactive 
antibodies to other related (Leptospira, Treponema, relapsing 
fever Borrelia) and nonrelated (Salmonella, Pseudomonas, Neisseria) 
bacterial species have been described.13 Cross-reactions with 
leptospiral and treponemal antibodies were not found by the 
specific tests and relapsing fever is not reported in Cuba.
The presence of specific antibodies in the individuals not 
always means Borrelia disease, due to clinical or subclinical 
infection occurrence in the past.5 Therefore, in our study, people 
with positive blots suggest previous contact with the infectious 
agent, since antibodies persist long time after the original 
infection. The estimated seroprevalence interval in the studied 
population is relatively low. However, it is necessary to keep in 
mind that Lyme disease is not officially reported in Cuba; that 
is why any evidence or finding about it is relevant. 
Similar studies in other Latin American countries have been 
reported. In Mexico, the first study of seroprevalence of IgG 
antibodies against the strain B31 by Western blot, showed 0.3% 
as positivity rate during 199914 and in a following study, rates 
of 3.43% and 6.2% were reported in different regions;15 all these 
rates are within the confidence interval estimated in our study. 
Other non-endemic countries have also reported low rates 
of seroprevalence in blood donors and higher rates in forestry 
workers or farmers, providing serological evidences of B. 
burgdorferi infection.16,17
In countries where Lyme borreliosis is frequent, the 
seroprevalence rates depend on the studied region and on 
the occupational characteristics of the population. Antibodies 
against B. burgdorferi have been more frequent in agricultural 
and forestry workers (7.03%) than in blood donors (3.56%). 
Nevertheless, in forestry rangers from Northeastern Italy the 
rates are much higher (23.2%).18,19 Rates of 31.3% and 12.8% 
have been reported in populations from a mountainous area 
of Spain and from Slovakia, respectively.20,21 We studied a 
sample of a population considered at risk, as they inhabit in 
a rural and mountainous area with a high level of tick 
infestation during years. A clinical and/or epidemiological 
correlation with laboratory results was not possible because a 
questionnaire was not applied to the subjects enrolled in the 
study, important aspect to consider in future investigations.
The importance of interpreting Western blot results 
according to the characteristics of Lyme disease in a local area at 
risk has been emphasized by different authors. Laboratories in 
countries with a low prevalence of Lyme borreliosis prefer to use 
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a rule that gives a higher specificity at the expense of sensitivity. 
Lyme borreliosis is not the same in all geographic areas due to 
different local prevalence of species and strains of B. burgdorferi 
sensu lato and also to the heterogeneity of strains. For these 
reasons, the recommendations for the interpretation of blots 
have not always been applicable to population in geographic 
areas other than where they were developed.22 
Nineteen antigenic bands, ranged from 14 to 90/93 kDa, 
were detected on immunoblots, and from 0 to 12 bands were 
regularly recognized by each serum. Most sera reacted with 4-7 
proteins and only a few sera reacted with 8-12 proteins. The 
average number of bands seen on immunoblots was 5.3 ± 1.9. 
The number of reactive bands on blots was low in 
comparison with the positive control blots (up to 21 bands were 
revealed), but was superior than the negative control blots 
(2-3 faint bands maximum), and this means that some other 
reactions were developed with different intensity degrees. 
Average numbers of reactive bands from 6.7 ± 4.1 to 8.7 ± 4.1 in 
early Lyme disease patients, 4.1 ± 2.6 in healthy donors and 3.7 ± 2.3 
in other illness patients have been reported on IgG immunoblots.23 
The number of reactive proteins in our investigation was superior 
to those for healthy donors and other ill patients. 
Fig. 1 summarizes the frequencies of recognition of each 
band and its intensities. The 90/93, 72, 60, 56, 47, 41, 34 and 
31 kDa bands were significantly revealed on blots, being the 
bands of 72, 60, 47 and 41 kDa detected in more than 50% of 
the samples. In most of the blots, the protein bands were 
recognized at a low intensity interpreting the results as weak. 
Fig. 2 shows the results obtained when analyzing only 
the blots estimated as positive. Ten proteins turned out as 
significant for the IgG immunoblot. In decreasing order of 
significance, these were 41, 72, 90/93, 34, 47, 60, 58, 56, 65/66 
and 31 kDa. The 41, 90 and 72 kDa proteins were detected in all 
positive tested sera. The estimated positive sera gave reactions 
with 8 or more protein bands and the stronger results were 
more frequent, although the reactivity of specific bands for 
B. burgdorferi sensu stricto was superior in the zones of 
90/93 kDa and 58-56 kDa. 
Fig. 1 – Frequencies of recognition and intensity of the borrelial protein bands on immunoblots (n = 247) using sera from 
the studied population.
Fig. 2 – Recognition and intensity of the borrelial protein bands by the sera and estimated as positives on immunoblots (n = 11).
14
18/20
22/24
28/29
30
33
34
39
41
43
45
47
56
58
60
65/66
72
83
90/93
14
18/20
22/24
28/29
30
33
34
39
41
43
45
47
56
58
60
65/66
72
83
90/93
0 10 20 30 40 50 60 70 80 90 100
     Frequency (%)
0 1 2 3 4 5 6 7 8 9 10 11
     # of sera
Strong result
Weak result
Strong result
Weak result
Pr
ot
ei
n
 b
an
d
 (k
D
a)
Pr
ot
ei
n
 b
an
d
 (k
D
a)
 BRAZ J INFECT DIS. 2012;16(1):82-85 85
Antibodies to highly specific and non-specific borrelial 
proteins were detected, but the analysis of these should not 
be done in an individual way because there are non-specific 
proteins that have value when they are detected together with 
specific proteins. Thus, the 72 kDa heat shock protein and 41 kDa 
flaggelin-proteins, the mainly revealed proteins in this study, are 
not specific for Borrelia because cross reactivities to many other 
bacteria are reported. However, they were observed together with 
the 90/93 kDa surface protein, a highly specific borrelial protein. 
A broad band pattern between 60 and 90/93 kDa is a support 
for the diagnosis of chronic Lyme disease and, among the most 
significant proteins in our study, the 60 and 65 kDa proteins 
were also observed. The heat shock protein p60 is recognized by 
cross-reactive antibodies, and according to a study of EUCALB, 
the inclusion of this protein in the combination for interpreting 
a Western blot caused slightly superior reactivities.23
Other highly specific borrelial proteins revealed on blots are 
the 34 (OspB), 31 (OspA), 30 and 22/24 (OspC) kDa proteins. The 
number of sera that reacted with these proteins was lower, 
but the immunoresponse to OspA is rare. The development of 
antibody reactivity occurs towards the beginning of prolonged 
arthritic episodes. OspC is the best and earliest marker for early 
Lyme disease and it is especially detected in IgM blots.24
The most reliable bands for the detection of antibodies against 
B. burgdorferi B31 by IgG Western blot in European patients were 
those representing the 93, 39, 34, and 23-kDa proteins.25 These 
proteins were also detected in the Cuban sera studied, except p39. 
In conclusion, the serological data indicated that the agent 
of Lyme borreliosis circulates with a relatively low prevalence 
in the population under study. These findings represent further 
data to support the previous serological findings6-8 suggesting 
the presence of this borreliosis in Cuba, and emphasizing the 
epidemiological alert for the national health authorities.
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